Vitaxin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-v beta-3 integrin |
| Clinical data | |
| Trade names | Vitaxin |
| ATC code |
|
| Identifiers | |
| DrugBank | |
| ChemSpider |
|
  (what is this?) | |
Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]
Vitaxin is safe for humans. It has little effect on advanced cancer.[3]
References
[edit]- ^ Cherrington JM, Strawn LM, Shawver LK (2000). Vande Woude GF, Klein G (eds.). "New paradigms for the treatment of cancer: the role of anti-angiogenesis agents". Advances in Cancer Research. 79. Academic Press: 1–38 (27). doi:10.1016/s0065-230x(00)79001-4. ISBN 978-0-12-006679-7. PMID 10818676.
- ^ Wilder RL (November 2002). "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases. 61 (Suppl 2): ii96–ii99. doi:10.1136/ard.61.suppl_2.ii96. PMC 1766704. PMID 12379637.
- ^ a b McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–7860. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408. S2CID 33227412.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |